Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...